Dexcom (DXCM) legal chief sells 1,700 shares in 10b5-1 trade

Rhea-AI Filing Summary

Dexcom Inc. executive Michael Jon Brown, EVP and Chief Legal Officer, reported an open-market sale of 1,700 shares of common stock at $64.85 per share. The transaction occurred on March 16, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025.

After this sale, Brown directly holds 112,904 Dexcom shares. This figure includes 77,603 unvested restricted stock units that are scheduled to vest in tranches through March 8, 2029, reflecting a substantial continuing equity stake aligned with the company’s long-term performance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brown Michael Jon

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2026		S		1,700(1)	D	$64.85	112,904(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On November 26, 2025, Mr. Brown adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Brown. The shares set forth above were sold pursuant to the 10b5-1 Plan.

2. Included in this number are 77,603 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 11,399 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Michael Jon Brown	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Dexcom (DXCM) report for Michael Jon Brown?

Dexcom reported that EVP and Chief Legal Officer Michael Jon Brown sold 1,700 shares of common stock at $64.85 per share on March 16, 2026. The transaction was an open-market sale executed under a pre-arranged Rule 10b5-1 trading plan.

Was the Dexcom (DXCM) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states Brown adopted a Rule 10b5-1 trading plan on November 26, 2025, allowing orderly share dispositions. The 1,700 shares sold on March 16, 2026 were executed pursuant to this pre-arranged plan rather than a discretionary same-day decision.

How many Dexcom (DXCM) shares does Michael Jon Brown hold after the sale?

Following the March 16, 2026 transaction, Brown directly holds 112,904 Dexcom common shares. This total includes both vested shares and 77,603 unvested restricted stock units scheduled to vest over several years, indicating a continued significant equity position in the company.

What unvested Dexcom (DXCM) restricted stock units does Brown retain?

Brown’s post-transaction holdings include 77,603 unvested restricted stock units. These consist of awards granted on March 8, 2024, March 8, 2025, and March 8, 2026, with vesting schedules extending through March 8, 2029, supporting long-term incentive alignment with Dexcom’s performance.

What role does Michael Jon Brown hold at Dexcom (DXCM)?

Michael Jon Brown serves as Executive Vice President and Chief Legal Officer at Dexcom. His Form 4 filing reflects personal equity activity in Dexcom common stock, providing transparency into transactions by a senior legal and executive officer of the company.